Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase 3 2Phase 1/2 2

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × HBI-8000 × Clear all
NCT05281276 2024-12-20

Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

Taipei Medical University Shuang Ho Hospital

Phase 1 Terminated
9 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02569489 2022-07-18

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

HUYABIO International, LLC.

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT02697552 2017-01-12

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

HUYABIO International, LLC.

Phase 1 Completed
13 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡